期刊文献+

溴隐亭在2型糖尿病中的应用进展 被引量:4

原文传递
导出
摘要 糖尿病是一种由多病因引起的以慢性高血糖为特征的终身性代谢性疾病,严重影响着患者的生活质量,治疗糖尿病的药物很多,诸如格列齐特、二甲双胍、阿卡波糖等。最近溴隐亭已开始被临床应用于治疗糖尿病,临床医师对溴隐亭的治疗效果充满了期待,且对溴隐亭的作用机制也怀有好奇心,溴隐亭治疗糖尿病的效果到底如何,我们将对国内外的研究结果进行详述,并对其降糖机制做简要的解释。
出处 《中华全科医学》 2016年第1期119-121,共3页 Chinese Journal of General Practice
基金 国家自然科学基金(81070637) 山东省科技发展计划项目(2010GSF10228 2012GGH11862) 山东省自然基金(Y2008C73 ZR2010HM044)
  • 相关文献

参考文献27

  • 1Holt RI,Barnett AH,Bailey CJ. Bromocriptine : old drug,new formula-tion and new indication [ J ]. Diabetes Obesity and Metabolism, 2010,12(12) :1048-1057.
  • 2Rastogi A, Walia R,Dutta P,et al. Efficacy and safety of rapid escala-tion of cabergoline in Comparison to conventional regimen for macrop-rolactinoma :aprospective randomized-trial [ J ]. Indian J EndocrinolMetab,2012,16(suppl 2) :S294-296.
  • 3Gaziano JM,Cincotta AH,0,Connor CM,et al. Randomized clinicaltrial of quick-release bromocriptine among patients with type 2 diabe-tes on overall safety and cardiovascular outcomes[ J]. Diabetes Care,2010,33(7) :1503-1508.
  • 4石维,许宇静,洪侃.Cycloset治疗2型糖尿病的研究进展[J].实用临床医药杂志,2011,15(13):144-146. 被引量:5
  • 5Dosa PI, Ward T, Waiters MA, et al. Synthesis of novel analogs ofcabergoline : improving cardiovascular safety by removing 5-HT2B re-ceptor agonism [ J] . ACS Med Chem Lett,2013 ,4(2) :254-258.
  • 6Seow KM,Lin YH,Bai CH,et al. Clinical outcome according to timingof cabergoline initiation for prevention of OHSSfl randomized controlledtrial[ J]. Reprod Biomed 0nline,2013 ,26(6) :562-568.
  • 7Nak D,Nak Y, Simsek G. Comparison of the use of cabergoline andgonadotrophin to treat primary and secondary anoestrus in bitches[J]. Aust Vet J,2012,90(5) :194-196.
  • 8包薇萍,郑仁东,刘超.溴隐亭降糖及减重的研究进展[J].中国糖尿病杂志,2013,21(4):370-372. 被引量:5
  • 9Kerr JL,Timpe EM,Petkewicz KA. Bromocriptinemesylate for giycemicmanagement in type 2 diabetes mellitus[ J]. Ann Pharmacother,2010,44(11) :1777-1785.
  • 10Mikhail N. Quick-release bromocriptine for treatment of type 2 diabe-tes[ J]. Curr Drug Deliv,2011,8(5) :511-516.

二级参考文献26

  • 1Brooks A M, Thacker S M. Dapagliflozin for the treatment of type 2 diabetes [ J ]. Ann Pharmacother, 2009, 43 ( 7 ) : 1286.
  • 2Monti JM, Monti D. The involvement of dopamine in the modulation of sleep and waking[J]. Sleep Med Rev, 2007, 11(2): 113.
  • 3Cineotta A. Hypothalamic role in the insulin resistance syn- drome//[M]. Hansen B, Shaffrir E. Reistance and insulin resistance syndrome. London :Taylor & Francis, 2002: 271.
  • 4Cineotta A H, Meier A H. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects [J]. Diabetes Care, 1996, 19(6): 667.
  • 5Veroseienee. Cycloset Package Insert, 2009. FDA approved label. Available from: http://www, aeeessdata, fda. gov/ drugsatfda-docs/label/2009/O208661bl, pdf [ Last acce.ssed 23 September 2009 ].
  • 6Luo S, Ezrokhi M, Trubitsyna Y , et al. Intrahypothalamic circuitry regulating hypothalanlic fuel sensing to induce insulin sensitivity or insulin resistance [abstract] [] ]. Diabetologia, 2008, 51(Suppl l) :S59.
  • 7Luo S, Luo J, Meier AH, et al. Dopaminergic neurotoxin administration to the area of the suprachiasmatie nuclei in- duces insulin resistance [J ]. Neuroreport, 1997, 8 ( 16 ) : 3495.
  • 8Cincotta AH, Luo S, Zhang Y, et al. Chronic infusion of norepinephrine into the VMH of nomml rats induces the obese glucose-intolerant state[J]. AmJ Physiol Regul Inte- gr Comp Physiol, 2000, 278(2) :R435.
  • 9Cincotta All, Meier AH, Cincotta M Jr. Bromocriptine im- proves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of dia- betes[J]. Expert Opin Investig Drugs, 1999, 8(10) : 1683.
  • 10Loew DM. Effects on the central nervous system//[ M ]. Berde H, Schild H. Ergot alkaloids and related compounds. New York: Springer- Verlag, 1978:421.

共引文献7

同被引文献53

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部